Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Article
[키워드] age
analysed
antibodies
B.1.1.7
B.1.351
Beta
binding
BNT162b2
BNT162b2 mRNA vaccine
boost
CD4 T cells
cells
circulating
cytokine
detectable
Efficacy
elderly
first dose
Frequency
Gamma
healthcare
heterogeneity
high-risk population
IgA
IgG
immune response
individual
individuals
information
interferon-γ
lack
less
measure
memory B cell
mRNA vaccination
neutralization
neutralization activity
neutralization potency
non-responder
Older
P.1
participant
Participants
provide
reduction in
Responder
SARS-CoV-2
SARS-CoV-2 spike-specific
SARS-CoV-2 vaccine
second dose
secreted
serum
T cell
titres
vaccination
Vaccine
vaccine dose
vaccine response
variants of concern
VoC
wild-type virus
[DOI] 10.1038/s41586-021-03739-1 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41586-021-03739-1 PMC 바로가기 [Article Type] Article